CD274 and neoplasm: The three FDA‐approved immunotherapy efficacy indicators, including programmed‐death ligand‐1 (PD‐L1) expression,3 microsatellite instability (MSI),4 and tumor mutation burden (TMB)5 exhibit remarkable effects in clinical practice.